B Acute Lymphoblastic Leukemia

Oncology·MeSH: Burkitt Lymphoma

Prevalence

8.0 / 100K

Incidence

1.8 / 100K/yr

64 drugs in development·8 companies·14 clinical trials

Drug Pipeline by Phase

Phase 3(57)
DrugCompany
Asparaginase Erwinia chrysanthemiAssertio Holdings, Inc. (ASRT)
Asparaginase Erwinia chrysanthemiCosmos Health Inc. (COSM)
Bleomycin SulfateAXIM BIOTECHNOLOGIES, INC. (AXIM)
BlinatumomabAXIM BIOTECHNOLOGIES, INC. (AXIM)
BlinatumomabCrinetics Pharmaceuticals, Inc. (CRNX)
BlinatumomabCosmos Health Inc. (COSM)
Calaspargase PegolMerus N.V. (MRUS)
Calaspargase PegolCosmos Health Inc. (COSM)
Calaspargase PegolAXIM BIOTECHNOLOGIES, INC. (AXIM)
CytarabineCrinetics Pharmaceuticals, Inc. (CRNX)
CytarabineAXIM BIOTECHNOLOGIES, INC. (AXIM)
CytarabineAssertio Holdings, Inc. (ASRT)
CytarabineCosmos Health Inc. (COSM)
DasatinibCosmos Health Inc. (COSM)
DasatinibAXIM BIOTECHNOLOGIES, INC. (AXIM)
DasatinibCrinetics Pharmaceuticals, Inc. (CRNX)
DaunorubicinAssertio Holdings, Inc. (ASRT)
DaunorubicinCosmos Health Inc. (COSM)
Daunorubicin HydrochlorideAssertio Holdings, Inc. (ASRT)
Daunorubicin HydrochlorideAXIM BIOTECHNOLOGIES, INC. (AXIM)
Dexrazoxane HydrochlorideAssertio Holdings, Inc. (ASRT)
ImatinibCosmos Health Inc. (COSM)
Inotuzumab OzogamicinAXIM BIOTECHNOLOGIES, INC. (AXIM)
Inotuzumab OzogamicinFilana Therapeutics Inc. (FLNA)
LeucovorinAXIM BIOTECHNOLOGIES, INC. (AXIM)
LeucovorinCosmos Health Inc. (COSM)
Leucovorin CalciumCosmos Health Inc. (COSM)
Leucovorin CalciumAXIM BIOTECHNOLOGIES, INC. (AXIM)
Liposome-encapsulated Daunorubicin-CytarabineAssertio Holdings, Inc. (ASRT)
MercaptopurineENANTA PHARMACEUTICALS INC (ENTA)
MercaptopurineAssertio Holdings, Inc. (ASRT)
MercaptopurineCosmos Health Inc. (COSM)
Mercaptopurine Oral SuspensionAssertio Holdings, Inc. (ASRT)
Mercaptopurine Oral SuspensionCosmos Health Inc. (COSM)
MesnaAssertio Holdings, Inc. (ASRT)
MesnaMerus N.V. (MRUS)
MesnaCrinetics Pharmaceuticals, Inc. (CRNX)
MesnaAXIM BIOTECHNOLOGIES, INC. (AXIM)
Mitoxantrone HydrochlorideAssertio Holdings, Inc. (ASRT)
PegaspargaseCosmos Health Inc. (COSM)
PegaspargaseENANTA PHARMACEUTICALS INC (ENTA)
PegaspargaseMerus N.V. (MRUS)
PegaspargaseAXIM BIOTECHNOLOGIES, INC. (AXIM)
PonatinibENANTA PHARMACEUTICALS INC (ENTA)
Ponatinib HydrochlorideAXIM BIOTECHNOLOGIES, INC. (AXIM)
Ponatinib HydrochlorideCrinetics Pharmaceuticals, Inc. (CRNX)
Procarbazine HydrochlorideAXIM BIOTECHNOLOGIES, INC. (AXIM)
ThioguanineMerus N.V. (MRUS)
ThioguanineCosmos Health Inc. (COSM)
ThioguanineENANTA PHARMACEUTICALS INC (ENTA)
Vinblastine SulfateAXIM BIOTECHNOLOGIES, INC. (AXIM)
VincristineAXIM BIOTECHNOLOGIES, INC. (AXIM)
VincristineCosmos Health Inc. (COSM)
Vincristine SulfateCosmos Health Inc. (COSM)
Vincristine SulfateAssertio Holdings, Inc. (ASRT)
Vincristine SulfateCrinetics Pharmaceuticals, Inc. (CRNX)
Vincristine SulfateAXIM BIOTECHNOLOGIES, INC. (AXIM)

Compare drugs

Asparaginase Erwinia chrysanthemi vs Bleomycin SulfateAsparaginase Erwinia chrysanthemi vs BlinatumomabAsparaginase Erwinia chrysanthemi vs Calaspargase Pegol

Frequently asked questions

How many drugs are in development for B Acute Lymphoblastic Leukemia?

BioSniper tracks 64 drugs in development for B Acute Lymphoblastic Leukemia across 8 companies.

How many clinical trials target B Acute Lymphoblastic Leukemia?

There are 14 clinical trials targeting B Acute Lymphoblastic Leukemia tracked by BioSniper.

What is the prevalence of B Acute Lymphoblastic Leukemia?

The estimated prevalence of B Acute Lymphoblastic Leukemia is approximately 8.0 per 100,000 population.

Deep-dive into B Acute Lymphoblastic Leukemia

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    B Acute Lymphoblastic Leukemia — Drugs in Development & Clinical Trials | BioSniper